Predicting Failure of Salvage Focal Ablation for Prostate Cancer

What is it about?

In this study, the authors externally validated a model predicting failure within 2 years after salvage focal ablation in men with localized radiorecurrent prostate cancer using prospective, UK multicentre dataset. The model was developed using a composite failure outcome and was assessed at 2 years post-salvage with discrimination, calibration, and decision curve analysis. The model demonstrated modest discrimination but good calibration and clinical utility for predicting failure of salvage focal ablation within 2 years. In decision curve analysis, there was incremental net benefit vs a 'treat all' strategy at risk thresholds of ≥0.23. The net benefit was higher across the majority of the 0.14-0.52 risk threshold range, and all of the 0.26-0.36 range. The model could be reasonably used to guide clinical decision-making in this patient population.

Featured Image

Why is it important?

This research is important because it externally validates a previously published model predicting failure within 2 years after salvage focal ablation in men with localized radiorecurrent prostate cancer. This model can help clinicians identify patients who are at a higher risk of treatment failure and may not benefit from salvage focal ablation, allowing for more personalized treatment decisions. Key Takeaways: 1. The model demonstrated modest discrimination but good calibration and clinical utility for predicting failure of salvage focal ablation within 2 years. 2. The model could be reasonably used to guide treatment decisions for patients with localized radiorecurrent prostate cancer. 3. The model offers net benefit for clinicians across the majority of risk thresholds in the range 0.14-0.52 and for all risk thresholds in the range 0.26-0.36. 4. A nomogram is provided to facilitate clinical use of the model, with risk groups detailing patients who would benefit from alternative discussions of whole-gland treatments or multimodal therapy. 5. The model should be used in conjunction with clinical judgment and individual patient factors, as it does not recommend specific next steps for patients who experience the composite failure outcome.